SCHEDULE 13G/A 0000950170-25-021707 0001388325 XXXXXXXX LIVE 2 Common Stock, par value $0.0001 per share 06/30/2025 0001868279 ArriVent BioPharma, Inc. 0472N1020 18 Campus Boulevard, Suite 100 Newtown Square PA 19073 Rule 13d-1(c) Novo Holdings A/S G7 1872142.00 0.00 1872142.00 0.00 1872142.00 4.9 CO ArriVent BioPharma, Inc. 18 Campus Boulevard, Suite 100, Newtown Square, PA, 19073. Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the "Foundation"), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies, currently comprised of Novo Nordisk A/S and Novozymes A/S (also known as Novonesis A/S), and is responsible for managing the Foundation's assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S. Tuborg Havnevej 19 2900 Hellerup, Denmark Denmark Y 1,872,142 4.99% 1,872,142 0 1,872,142 0 N Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Novo Holdings A/S Barbara Fiorini 08/14/2025